WealthPLAN Partners LLC Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

WealthPLAN Partners LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 23.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,166 shares of the biopharmaceutical company’s stock after selling 3,086 shares during the period. WealthPLAN Partners LLC’s holdings in Pfizer were worth $282,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Clifford Capital Partners LLC raised its stake in Pfizer by 29.3% during the first quarter. Clifford Capital Partners LLC now owns 442,593 shares of the biopharmaceutical company’s stock worth $12,282,000 after purchasing an additional 100,210 shares during the period. KCM Investment Advisors LLC raised its stake in shares of Pfizer by 2.5% in the 1st quarter. KCM Investment Advisors LLC now owns 143,467 shares of the biopharmaceutical company’s stock valued at $3,981,000 after acquiring an additional 3,431 shares during the period. Tectonic Advisors LLC raised its stake in shares of Pfizer by 2.8% in the 1st quarter. Tectonic Advisors LLC now owns 130,504 shares of the biopharmaceutical company’s stock valued at $3,621,000 after acquiring an additional 3,571 shares during the period. Oppenheimer & Close LLC raised its stake in shares of Pfizer by 0.3% in the 1st quarter. Oppenheimer & Close LLC now owns 144,860 shares of the biopharmaceutical company’s stock valued at $4,020,000 after acquiring an additional 500 shares during the period. Finally, NTV Asset Management LLC raised its stake in shares of Pfizer by 2.7% in the 1st quarter. NTV Asset Management LLC now owns 66,775 shares of the biopharmaceutical company’s stock valued at $1,853,000 after acquiring an additional 1,781 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.1 %

PFE stock traded down $0.02 during mid-day trading on Monday, hitting $28.90. 8,900,903 shares of the company were exchanged, compared to its average volume of 39,777,379. The company has a market capitalization of $163.76 billion, a PE ratio of -481.25, a price-to-earnings-growth ratio of 1.13 and a beta of 0.69. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.80. The firm has a fifty day simple moving average of $28.25 and a 200 day simple moving average of $27.71.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the firm earned $1.23 EPS. The company’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, research analysts forecast that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.81%. The ex-dividend date is Friday, July 26th. Pfizer’s payout ratio is -2,799.53%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research reports. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Morgan Stanley raised their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, July 10th. Finally, Barclays raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 10th. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $34.50.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.